CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain

AHF • Victory! AHF Kills Gilead’s Greedy Drug Price Hikes

Groups welcome reversal of Gilead’s price-gouging decision that would have resulted in fewer people with HIV getting access to lifesaving treatment.   WASHINGTON (October 29, 2025) – AIDS Healthcare Foundation (AHF) was victorious in killing Gilead Sciences’ plan to institute high-single digit price hikes for several of its HIV medications, hikes that would have gutted the nation’s AIDS Drug Assistance Programs (ADAPs).   Last week, following mo…

CDC Endorses Twice-Yearly HIV Prevention Drug Yeztugo, But Access Barriers Remain

In a significant advancement for HIV prevention, the Centers for Disease Control and Prevention (CDC) has issued a strong recommendation for Yeztugo (lenacapavir), Gilead Sciences’ long-acting, twice-yearly pre-exposure prophylaxis (PrEP) medication. This endorsement, published in the CDC’s Morbidity and Mortality Weekly Report on September 18, marks a pivotal moment in the effort to expand HIV […]